Loading clinical trials...

RECRUITING

Cognitive Screening in Lung Cancer Patients

NCT06727370•European Institute of Oncology

Summary

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
•Age ≥ 18 years
•Patients able to speak and read the local language(s) fluently
•Acceptance and signature of informed consent

Exclusion Criteria

•Age ≥ 70
•Presence of brain metastases
•Patients with concomitant neurological or psychiatric disorders.
•Patients undergoing brain radiotherapy
•Previous diagnosis of lung cancer

Locations (1)

Istituto Europeo di Oncologia

Milan, Italy

Key Dates

Start Date

January 10, 2024

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

December 10, 2024

Enrollment

200

ESTIMATED participants

Conditions

Lung DiseaseNSCLC (Non-small Cell Lung Cancer)SCLC

Contacts

Gabriella Pravettoni

CONTACT

+39025489731 gabriella.pravettoni@ieo.it

Lorenzo Conti

CONTACT

+390257489731

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

RECRUITING

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 10, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cognitive Screening in Lung Cancer Patients

Inclusion Criteria

Exclusion Criteria

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

Magnetic Resonance Imaging of the Lung: Oncological Applications

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)